JP5061143B2 - Topical skin preparation - Google Patents

Description

  The present invention relates to an external preparation for skin, and particularly to an external preparation for skin that is effective in improving pruritus and dryness and excellent in feeling of use.

  Conventionally, patients suffering from pruritus due to skin diseases such as atopic dermatitis have used steroids and anti-inflammatory agents to suppress itching and inflammation. However, steroidal agents such as corticosteroids, which are the main treatment methods, have a remarkable effect, but on the other hand, some patients may develop side effects. As side effects seen in steroids, for example, skin atrophy, hirsutism, flushing, rebound phenomenon when use is stopped, and the like are known. Thus, since existing steroids that are widely used for the treatment of skin diseases and pruritus caused by them have fears of side effects, there is a strong need for external preparations that have fewer side effects and are highly safe and can be used with confidence. Has been. Among these, as a skin-friendly external preparation using a natural extract, those containing at least one extract of shrimp belonging to the genus Ebine of the Orchidaceae plant (Patent Document 1), grape genus plant, and itidae plant One containing at least one selected (Patent Document 2) is known.

JP-A-10-139676 JP 2002-47193 A

However, the external preparation formulated with the natural extract was preferable in that no side effects were observed, but the skin external preparation for improving pruritus has anti-histamine, anti-inflammatory, antibacterial and moisturizing effects. It was insufficient in terms.
The present invention has been made in view of the above problems, and an object of the present invention is to provide an external preparation for skin that is effective in improving pruritus and drying and has an excellent feeling of use.

As a result of intensive studies by the present inventors in order to solve the above-mentioned problems, the use of a topical skin preparation containing mugwort extract, a high-concentration zinc-containing yeast extract, and lactoferrin can lead to skin diseases such as atopic dermatitis. The present inventors have found that an unpleasant symptom caused by pruritus, roughness, roughness, dryness, and rough skin can be reduced and a moisturizing effect can be obtained, and the present invention has been completed.
That is, the external preparation for skin according to the present invention comprises (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin.
It is preferable to use the external preparation for skin as a bath agent.
In the bath preparation, it is preferable that 0.001 to 1.0 g of (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin are contained as pure extracts in a 150-L dilution bath preparation, respectively. is there.
In the above-mentioned external preparation for skin, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin may be included as 0.001 to 0.1% as a pure extract in the topical external preparation for skin. Is preferred.

  According to the present invention, by blending (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin, it has an effect of being effective in improving pruritus and having excellent usability. .

The result in the antibacterial test using Candida albicans as a test bacterium. (A-1) and (A-2) are the results of the test sample containing lactoferrin and the test sample of only the solvent, respectively (B-1) and (B-2) are mugwort extract + high concentration zinc It is the result of the test sample which contained yeast extract + lactoferrin, and the test sample of only a solvent. It is the figure put together about the evaluation result of each evaluation item by the panel in a test example.

Hereinafter, preferred embodiments of the present invention will be described.
First, the external preparation for skin of the present invention can be used to improve pruritus and dryness. Among pruritus, it can be particularly preferably used for pruritus caused by atopic dermatitis, senile pruritus and dry skin.
The skin external preparation concerning this invention exhibits the following outstanding effects by mix | blending (a) mugwort extract, (b) high concentration zinc containing yeast extract, and (c) lactoferrin. That is, it has an IgE antibody production inhibitory effect, a histamine release inhibitory effect, an antibacterial effect, reduces discomfort caused by pruritus and bulkiness, has a moisturizing effect, and is excellent in use feeling.

(A) Artemisia extract used in the present invention is a plant belonging to the genus Artemisia. Among these, extracts obtained from Kawara mugwort, Korean mugwort, mugwort, mugwort mugwort, wormwood mugwort and the like can be preferably used. As the mugwort extract in the present invention, an extract or dilution obtained by extracting and preparing mugwort leaves at room temperature or under heating can be suitably used. The mugwort extract in the present invention is preferably blended in an amount of 0.001 to 0.1%, particularly preferably 0.005 to 0.05%, as a pure extract in a topical skin external preparation. When the content of mugwort extract to be blended in the external preparation for skin is less than 0.001%, sufficient IgE antibody production inhibitory effect and histamine release inhibitory effect cannot be obtained. Moreover, although the content of the mugwort extract blended in the external preparation for skin may be contained in excess of 0.1%, it is not preferable because the effect of the present invention is not so much improved.
In addition, content of the pure extract in this invention was calculated | required by subtracting added components, such as extract liquids, such as a water | moisture content and alcohol, from all extracts of extracts, such as a mugwort.

  The high-concentration zinc-containing yeast extract used in the present invention is obtained by culturing and extracting yeast using a medium supplemented with a zinc compound. High-concentration zinc in high-concentration zinc-containing yeast extract means that the yeast extract contains about 0.02% zinc, and contains about 10 times as much zinc as general yeast extract. . In addition, it can be obtained as yeast liquid ZB (made by Ichimaru Falcos) as a commercial item. The high-concentration zinc-containing yeast extract in the present invention is preferably blended in an amount of 0.001 to 0.1%, particularly preferably 0.005 to 0.05%, as a pure extract in a topical skin external preparation. If the content of the high-concentration zinc-containing yeast extract to be blended in the external preparation for skin is less than 0.001%, sufficient IgE antibody production inhibitory effect and histamine release inhibitory effect cannot be obtained. Moreover, although content of the high concentration zinc containing yeast extract mix | blended with a skin external preparation may contain exceeding 0.1%, since the improvement of the effect of this invention is not seen so much, it is unpreferable.

  (C) Lactoferrin used in the present invention is a non-heme iron-binding glycoprotein contained in mammalian milk, tears, saliva and the like. The lactoferrin in the present invention is preferably added in an amount of 0.001 to 0.1%, particularly preferably 0.005 to 0.05%, as a pure extract in the topical skin external preparation. When the content of lactoferrin blended in the external preparation for skin is less than 0.001%, sufficient IgE antibody production inhibitory effect and antibacterial effect cannot be obtained. Moreover, the content of lactoferrin to be blended in the external preparation for skin may be contained in excess of 0.1%, but this is not preferable because the effect of the present invention is not so much improved.

  In addition to the above essential components, the external preparation for skin of the present invention can be blended with raw materials usually used for external preparations for skin.

  The external preparation for skin of the present invention comprises (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin as essential components, optionally adding optional components and stirring uniformly with a stirrer. Etc., and can be produced by conventional methods. The dosage form of the external preparation for skin of the present invention is arbitrary, solution system, solubilization system, emulsification system, powder dispersion system, water-oil two-layer system, water-oil-powder three-layer system, lotion, cream, gel, Any dosage form such as mist, spray, ointment, etc. may be used.

  The external preparation for skin according to the present invention is preferably used as a bath agent. By using the external preparation for skin according to the present invention as a bath agent, it is possible to function as a form of systemic administration even for patients suffering from pruritus with a wide onset area in many skin diseases. That is, skin diseases such as senile pruritus and atopic dermatitis often occur throughout the body, and it may be difficult to apply a wide range of external preparations for application. Further, in the case of elderly people, particularly patients with dementia, topical application of external preparations by the patient himself may be more difficult. Even in such a case, by using the external preparation for skin according to the present invention as a bath agent, it can be easily applied over a wide range by the patient himself / herself, a family other than the patient, and medical personnel. Furthermore, the dosage form of the bath preparation concerning this invention is not specifically limited, It can be set as a powder, a granule, a tablet, a liquid, an emulsified state, etc.

  When the skin external preparation according to the present invention is used as a bath agent, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin as a pure extract in a 150 L dilution bath agent, respectively. It is preferable to include 1.0 g, and it is particularly preferable to include 0.01 to 0.1 g. When the content of each component blended in the bath agent is less than 0.001 g, sufficient IgE antibody production inhibitory effect, histamine release inhibitory effect and antibacterial effect cannot be obtained. Moreover, although content of each component mix | blended with an external preparation for skin may contain 1.0g or more, since the improvement of the effect of this invention is not seen so much, it is unpreferable.

The skin external preparation of the present invention thus obtained comprises an IgE antibody production inhibitory effect, a histamine release inhibitory effect, an antibacterial effect by blending (a) mugwort extract, (b) a high concentration zinc-containing yeast extract, and (c) lactoferrin. It has an effect, reduces discomfort caused by pruritus and dryness, and is excellent in use feeling.
EXAMPLES The present invention will be specifically described below with reference to examples, but the technical scope of the present invention is not limited to these examples.

First, in order to confirm that (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin is effective for skin diseases, IgE antibody production inhibition test, histamine A release inhibition test and an antibacterial test were conducted.
In the following examples, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin are Falcolex kawara mugwort extract B, yeast liquid ZB, and lactoferrin S (all manufactured by Ichimaru Falcos), respectively. Using. The component composition of each product is shown below.

・ Falco Rex Kawara mugwort B
Extract composition (%)
Kawara mugwort 0.50
Butylene glycol 29.85
Water 69.65
・ East Liquid ZB
Extract composition (%)
High-concentration zinc-containing yeast (*) 1.4
Butylene glycol 25.0
Glycerin 4.9
Water 68.7
*: Contained zinc is about 10 times the amount of zinc contained in normal yeast extract. Lactoferrin S
Extract composition (%)
Lactoferrin 1.5
Butylene glycol 20.0
Ethanol 10.0
Water 68.5

IgE antibody production suppression test (a) Artemisia extract, (b) High concentration zinc-containing yeast extract, (c) The effect of lactoferrin on IgE production suppression was examined and examined. Patients with atopic dermatitis have high IgE levels in the blood. Therefore, a substance that suppresses the production of IgE antibody can be expected to be applied to anti-atopic dermatitis.

Test method Test samples shown in Table 1 below (0.15 ml when used alone, 0.15 ml when using two components x 2 = 0.3 ml in total) were intraperitoneally administered to mice, and ovalbumin (Sigma) 24 hours later 10 μg, 0.3 mL of aluminum hydroxide gel (Sigma) and 2.7 mg of sodium chloride were added and mixed well, and immunized by injection into the abdominal cavity of mice. Two weeks after administration of the test substance, the test substance was again administered in the same manner, and after 24 hours, the antigen was administered in the same manner and boosted. One week after the booster immunization, blood was collected and IgE antibody in the serum was quantified by ELISA. Two mice were used per test sample, and measurement was performed twice per mouse. As a control, physiological saline that does not suppress IgE production was used. The IgE amount relative value and the IgE production inhibition rate compared with the physiological saline administration group were calculated by the following formula (Equation 1). The results are shown in Table 1.

(Equation 1)
Relative value of IgE amount = (IgE production amount of test sample administration group) / (IgE production amount of physiological saline administration group) × 100
IgE production inhibition rate = 100− (IgE amount relative value)

From Table 1, it can be seen that lactoferrin has a very high inhibitory effect on IgE antibody production. It can also be seen that addition of mugwort extract to lactoferrin further enhances the inhibition rate of lactoferrin alone. In addition, when lactoferrin and high-concentration zinc-containing yeast extract are mixed, the suppression rate increases from the sum of the respective suppression rates, and it can be seen that the mixing of these two components synergistically increases the IgE antibody production suppression effect.
From the above, it was found that the composition containing (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin can obtain an excellent IgE antibody production inhibitory effect.

Histamine Release Inhibition Test Next, tests were conducted on the histamine release inhibitory effect of (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin. In type I allergic reactions, it is known that chemical mediators such as histamine are released from sensitized mast cells and basophils. Therefore, a substance that suppresses histamine release reaction can be expected to have an antiallergic action.

-Preparation of test sample First, three samples were prepared in order to test each of (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin. A single sample was taken at 0.5 μl, and each sample was diluted 10-fold with purified water (to 5 μl with purified water) or 50-fold (to 25 μl with purified water) to prepare test samples.
After that, 4 specimens were prepared by mixing (a) and (b), (b) and (c), (a) and (c), and (a), (b) and (c). Prepared. In view of the efficacy of each component in a single test sample, the mixed specimens are 0.5 μl, 2.5 μl, and 2.5 μl each of components (a), (b), and (c), and each mixed component is purified water. Was diluted to 25 μl to prepare a test sample.

Test Method Rats were lethal to death under ether anesthesia, the skin was excised, a small hole was made in the midline abdominal wall, and Thailand containing approximately 15 mL of 2% FCS (fetal calf serum, GIBCO) was placed in the abdominal cavity. The load solution (2% FT solution) was injected, the abdominal wall was gently massaged, and the peritoneal exudate cell suspension was collected.
The peritoneal exudate cell suspension thus obtained was centrifuged at 500 rpm for 5 minutes at 4 ° C., and the precipitated cells were collected. The cell suspension after adding 2 mL of 2% FT solution and stirring gently was centrifuged at 4 ° C. and 500 rpm for 5 minutes, and this operation was repeated twice. The obtained mast cells were suspended in 2% FT solution so as to be about 1.0 × 10 ⁵ cells / mL, and the above-mentioned test sample (purified water in the control) was added to the cell suspension 120 μL on the plate, 37 After leaving still at 10 ° C. for 10 minutes, 40 μL of histamine releasing agent compound 48/80 (Sigma) (final concentration 1 μg / ml) preliminarily heated to 37 ° C. was added, and left still at 37 ° C. for 15 minutes. The reaction was stopped by cooling with ice, and the mixture was centrifuged at 100 xg for 10 minutes at 4 ° C. The histamine content in the supernatant was added with 25 μL of Shore-phtaldialdehyde-methanol solution and allowed to stand for 5 minutes, and then 3N HCl solution. The reaction was stopped at 25 μL, and 10 minutes after the completion of the reaction, centrifugation was performed at 5 ° C. and 1900 rpm for 25 minutes to obtain a supernatant and a sediment. The fluorescence of the supernatant was measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm. The amount of histamine in the supernatant was determined from the concentration histamine calibration curve. In addition, 4 plates were used for one test sample, and the average value of the 4 plates was defined as the amount of histamine. In addition, the amount of histamine remaining in the mast cells was measured by the same method as described above on the next day after cryopreserving a 125% FT solution with 2% FT solution and measuring the histamine release ratio and inhibition rate as follows. (2). The results are shown in Table 2 and Table 3.

(Equation 2)
Histamine release ratio = (Amount of histamine released from cells) / (Total amount of histamine in cells)
Histamine release inhibition rate (%) = [1− (A−C) / (B−C)] × 100
A: Release ratio of histamine when a test sample coexists with mast cells and a histamine releaser is added B: Release ratio of histamine when a histamine releaser is added to mast cells C: Histamine naturally released from mast cells Release ratio

From Table 2, the mugwort extract showed a high histamine release inhibitory effect. Moreover, from Table 3, it can be seen that, when lactoferrin or high-concentration zinc-containing yeast extract is mixed with mugwort extract, the inhibition rate of mugwort extract alone (51.5%) is greatly enhanced. Moreover, the histamine release inhibitory rate of the composition which mix | blended all three components of (a)-(c) was 80.5%.
From the above results, it was found that the combination of (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin has a histamine release inhibitory effect.

Antibacterial test Next, the antibacterial effect of (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin was tested and examined.

-Preparation of test sample First, three samples were prepared in order to test each of (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin. Each component was diluted 8 times with purified water and used as a test sample.
After that, 4 specimens were prepared by mixing (a) and (b), (b) and (c), (a) and (c), and (a), (b) and (c). Prepared. In view of the efficacy of each component in a single test sample, each mixed component was diluted 8-fold with purified water to produce a test sample.

Test method Liquid medium: 37 g of Brain Heart Infusion Broth (Eiken) was dissolved in 1000 mL of purified water and sterilized under pressure at 121 ° C. for 15 minutes. A test bacterial solution was obtained by adding 1 white fungus ear of test bacteria to 10 mL of this medium and culturing at 37 ° C. for 18 hours and diluting this medium 100-fold with the same medium. Further, 0.5 ml of this test bacterial solution was added to a test tube containing 0.5 ml of the above test sample, and cultured at 37 ° C. for 18 hours, and then the number of bacteria was measured.

  The results of the number of bacteria when Candida albicans is used as the test bacteria are shown in Table 4 below. Moreover, the photograph which image | photographed the result of the test sample which put lactoferrin and the test sample of only a solvent is shown to FIG. 1 (A-1) and FIG. 1 (A-2), respectively. In addition, (a) Artemisia extract + (b) High concentration zinc-containing yeast extract + (c) Photographs taken of test samples containing lactoferrin and solvent-only test samples are shown in FIG. 1 (B-1), As shown in FIG. Candida albicans is a bacterium that causes candidiasis (such as candidiasis rash and candidiasis). Therefore, substances that suppress Candida albicans can alleviate skin diseases and anti-candidiasis can be expected. This Candida spp. Is highly resistant to drugs, and the flora is dominant on the skin of patients with skin diseases such as atopic dermatitis, and the symptoms are often aggravated by unique strong itching. For this reason, Candida is one of the causes of difficult skin diseases.

From Table 4 and FIG. 1, it was found that lactoferrin has an antibacterial effect on Candida albicans. Moreover, the antibacterial effect was recognized also to the skin external preparation containing (a) mugwort extract of this invention, (b) high concentration zinc containing yeast extract, and (c) lactoferrin. Similarly, lactoferrin has an antibacterial effect on Staphylococcus aureus (also known as Staphylococcus aureus), which is frequently detected from skin lesions of atopic dermatitis.
From the above results, it was found that an antibacterial effect was obtained by combining (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin.

Next, the bath preparation was manufactured as a test example of the external preparation for skin according to the present invention with the formulation shown in Table 5. In the bath preparation method of the test example, first, 19.0% of water, 7.6% of butylene glycol, 0.3% of glycerin, Chinese mugwort and high-concentration zinc-containing yeast were stirred with a stirrer. Furthermore, after adding 66.6% of water and stirring, lactoferrin and the remaining components in Table 5 were added and stirred to obtain a liquid bath agent. In addition, the compounding quantity of Kawaramugi, high concentration zinc containing yeast, and lactoferrin is all the mass as a pure extract.
On the other hand, the bathing agent of Comparative Example was prepared by adding 60% anhydrous sodium sulfate and 40% sea salt to a mixing kettle and stirring.

  Forty panelists (8 males, 12 females, 1 year old to 75 years old) who are patients with skin diseases such as atopic dermatitis and senile pruritus, 30 ml of each obtained bathing agent was applied at 38 to 40 ° C. I put it in 150L of bath water and had it mix well. The bath was bathed once a day for about 10 minutes for 20 consecutive days. The evaluation items and evaluation criteria used in the test examples (20 persons) and comparative examples (20 persons) will be described below.

・ Evaluation criteria (1) Itching has improved remarkably ... 3
Slightly improved 2
Unchanged ... 1
Deteriorated ... 0
(2) Roughness has been remarkably improved ... 3
Slightly improved 2
Unchanged ... 1
Deteriorated ... 0
(3) Remarkably improved bulkiness ... 3
Slightly improved 2
Unchanged ... 1
Deteriorated ... 0
(4) Moist and moist ... 3
Unchanged ... 1
(5) It feels smooth and smooth ... 3
Unchanged ... 1
(6) Warmly warmed up ... 3
Slightly warmed ... 2
Unchanged ... 1

-Evaluation method The panelists evaluated each evaluation item according to the above evaluation criteria, and the average evaluation points are shown as shown in Table 6 below. Moreover, the actual evaluation result in a test example is shown in FIG.
Average evaluation score 2.3 to 3.0: ◎
2.0 to less than 2.3: ○
1.8 to less than 2.0: △
Less than 1.8: ×

From Table 6, it can be seen that in the test examples in which (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were blended, all evaluations were superior to the comparative examples. In the test example, although the evaluation item (2) was rough, the average evaluation score was △, but there was no evaluation that it deteriorated. From FIG. 2, it can be seen that about 70% of the panelists remarkably improved or slightly improved. .
From the above, by blending (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, (c) lactoferrin, the discomfort resulting from pruritus and bulkiness is reduced, and there is also a moisturizing effect, and also a feeling of use It was revealed that an excellent skin external preparation can be obtained.

  Although the formulation example of the skin external preparation concerning this invention is given to the following, the technical scope of this invention is not limited at all by this. All of the obtained external preparations for skin were effective in improving pruritus and dry skin, and were excellent in usability. For * 1, * 2, and * 3, Falcolex Kawaramugi Extract B, East Liquid ZB, and Lactoferrin S were used.

Formulation Example 1 Bathing agent (essence type)
Compounding amount (%)
Kawara mugwort extract (* 1) 20.00
High concentration zinc-containing yeast extract (* 2) 6.66
Lactoferrin (* 3) 6.66
1,3-butylene glycol 50.00
Ethanol 16.66
Sodium hyaluronate (2) 0.01
Succinyl atelocollagen solution 0.01
In Formulation Example 1, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were contained as pure extracts by 0.10%, 0.09%, and 0.10%, respectively.

Formulation Example 2 Bathing agent (milk type)
Compounding amount (%)
Kawara mugwort extract (* 1) 20.00
High concentration zinc-containing yeast extract (* 2) 6.66
Lactoferrin (* 3) 6.66
Mineral oil 32.95
Safflower oil 4.00
POE (20) cetyl ether 2.60
Sorbitan palmitate 2.80
Solveste tetraoleate 0.30
Dipropylene glycol 4.00
Diglycerin 6.50
Methylparaben 0.25
Edetate disodium 0.25
Polyethylene glycol 200 0.10
Dipotassium glycyrrhizinate 0.10
Sodium hyaluronate (2) 0.01
Succinyl atelocollagen solution 0.01
Fragrance 0.30
Pure water 12.51
In Formulation Example 2, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were contained as pure extracts in 0.10%, 0.09%, and 0.10%, respectively.

Formulation 3 Lotion
Compounding amount (%)
Kawara mugwort extract (* 1) 1.80
High concentration zinc-containing yeast extract (* 2) 0.60
Lactoferrin (* 3) 0.60
Alcohol 10.00
POE hydrogenated castor oil 0.20
Glycerin 5.00
Dipropylene glycol 3.00
Sodium hyaluronate 0.05
Succinyl atelocollagen solution 0.20
Methylparaben 0.05
Pure water 78.50
In Formulation Example 3, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were included as pure extracts in 0.009%, 0.008%, and 0.009%, respectively.

Formulation Example 4 Latex
Compounding amount (%)
Kawara mugwort extract (* 1) 1.80
High concentration zinc-containing yeast extract (* 2) 0.60
Lactoferrin (* 3) 0.60
Liquid paraffin 6.50
Stearic acid 1.50
Glycerol monostearate1.00
Cetostearyl alcohol 0.50
POE sorbitan monostearate 0.36
POE sorbitan monooleate 1.26
POE cetyl ether 0.18
Palm oil fatty acid sorbitan 0.50
Dimethicone 0.50
Butylparaben 0.05
Glycerin 2.00
Sodium hyaluronate 0.01
Succinyl atelocollagen solution 0.20
Pure water 82.44
In Formulation Example 4, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were contained as pure extracts in 0.009%, 0.008%, and 0.009%, respectively.

Formulation Example 5 Cream
Compounding amount (%)
Kawara mugwort extract (* 1) 1.80
High concentration zinc-containing yeast extract (* 2) 0.60
Lactoferrin (* 3) 0.60
Solid paraffin 11.00
Liquid paraffin 10.00
Cetanol 5.00
White petrolatum 5.00
Stearic acid 3.00
Butylparaben 0.05
Triethanolamine 1.35
Methylparaben 0.05
Sodium hyaluronate 0.01
Succinyl atelocollagen solution 0.20
61.34 pure water
In Formulation Example 5, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were contained as pure extracts in 0.009%, 0.008%, and 0.009%, respectively.

Formulation Example 6 Body Soap
Compounding amount (%)
Kawara mugwort extract (* 1) 1.80
High concentration zinc-containing yeast extract (* 2) 0.60
Lactoferrin (* 3) 0.60
Potassium hydroxide 5.54
Lauric acid 11.00
Myristic acid 4.00
Stearic acid 4.00
Edetate disodium 0.085
Methylparaben 0.20
Sodium chloride 0.70
Coconut oil fatty acid monoethanolamide 3.00
Laurolylmethylalanine sodium 1.00
Lauramidopropyl betaine 1.00
Lauryl sulfate triethanolamine 4.50
Glycol distearate 1.80
Glycerin 1.80
Hydroxypropyl methylcellulose 0.50
Fragrance 0.60
Water 57.275
In Formulation Example 6, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were contained as pure extracts in 0.009%, 0.008%, and 0.009%, respectively.

Formulation Example 7 Ointment
Compounding amount (%)
Kawamomogi Extract (* 1) 3.6
High concentration zinc-containing yeast extract (* 2) 1.2
Lactoferrin (* 3) 1.2
White petrolatum 25.0
Stearyl alcohol 20.0
Propylene glycol 12.0
POE hydrogenated castor oil 4.0
Glycerol monostearate 1.0
Propylparaben 0.1
Methylparaben 0.1
Pure water 31.8
In Formulation Example 7, (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin were contained as pure extracts in 0.018%, 0.017%, and 0.018%, respectively.

Claims (4)

(A) Artemisia extract,
(B) a high-concentration zinc-containing yeast extract;
(C) An external preparation for skin comprising lactoferrin.   A bath preparation comprising the external preparation for skin according to claim 1. The bath preparation according to claim 2, wherein (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin are each 0.001 to 1.0 g as a pure extract in a 150-liter dilution bath. A bath agent characterized by containing .   The external preparation for skin according to claim 1, wherein 0.001 to 0.1% of (a) mugwort extract, (b) high-concentration zinc-containing yeast extract, and (c) lactoferrin are each included as a pure extract in the external preparation. Topically applied skin external preparation characterized by the above.

Images